BRG1 regulation by miR-155 in human leukemia and lymphoma cell lines
-
M. Cuadros [1] ; V. Sánchez-Martín [1] ; Antonio Herrera-Merchan ; C. Baliñas [2] ; J. Martín-Padrón [1] ; L. Boyero [1] ; P. Peinado [2] ; P. P. Medina
-
[1] Universidad de Granada
Universidad de Granada
Granada, España
-
[2] GENYO, Centre for Genomics and Oncological Research Granada, España
-
- Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 19, Nº. 8 (August 21017), 2017, págs. 1010-1017
- Idioma: inglés
- Texto completo no disponible (Saber más ...)
-
Resumen
Introduction/purpose BRG1 is a key regulator of leukemia stem cells. Indeed, it has been observed that this type of cells is unable to divide, survive and develop new tumors when BRG1 is down-regulated.
Materials and methods We assessed BRG1 and miR-155 expression in 23 leukemia cell lines, and two no pathological lymphocyte samples using qPCR. MiR-155 transfection and western blot were used to analyze the relationship between miR-155 and its validated target, BRG1, by measuring protein expression levels. The effect of miR-155 on cell proliferation and prednisolone sensitivity were studied with resazurin assay.
Results BRG1 expression levels could correlate negatively with miR-155 expression levels, at least in Burkitt’s lymphoma and diffuse large B cell lymphoma (DLBCL) cell lines. To clarify the role of miR-155 in the regulation of BRG1 expression, we administrated miR-155 mimics in different leukemia/lymphoma cell lines. Our results suggest that miR-155 regulate negatively and significantly the BRG1 expression at least in the MOLT4 cell line.
Conclusion Our study revealed a previously unknown miR-155 heterogeneity that could result in differences in the treatment with miRNAs in our attempt to inhibit BRG1. However, the expression levels of BRG1 and miR-155, before prednisolone treatment were not statistically significantly associated prednisolone sensitive leukemia cells.
